Product image of Menovag (Estradiol) supplied by GNH India

Menovag

Active Ingredient:
Estradiol
Origin:
EU

Menovag (Estradiol)

Estradiol, the active ingredient in Menovag, is an estrogen presented as an unspecified strength vaginal tablet for vaginal use. It restores local estrogen levels in the vaginal epithelium, helping to alleviate symptoms associated with estrogen deficiency such as dryness, irritation, and discomfort in post‑menopausal women.

GNH India supplies Menovag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Manufacturer / TM Owner

Orion Corporation

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Menovag (estradiol) is used in estrogen‑dependent conditions of the female genital tract, primarily to address menopausal changes.
  • Vaginal atrophy: improves epithelial thickness and lubrication, reducing dryness and discomfort.
  • Genitourinary syndrome of menopause: alleviates dyspareunia, itching and urinary symptoms linked to estrogen loss.
  • Estrogen deficiency after oophorectomy: restores local estrogen activity to support vaginal health.

How It Works

  • Estradiol binds to intracellular estrogen receptors ERα and ERβ in vaginal and uterine tissues. The hormone‑receptor complex translocates to the nucleus, where it interacts with estrogen response elements on DNA, modulating transcription of genes that promote epithelial proliferation, increased glycogen production, and vascularization. These actions restore the normal structure and function of the vaginal mucosa.

Side Effects

Estradiol administered vaginally can be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Vaginal irritation or burning: mild discomfort at the application site.
  • Increased vaginal discharge: watery or milky secretion.
  • Breast tenderness: mild swelling or soreness.
  • Headache: transient mild headache.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Endometrial hyperplasia or carcinoma: abnormal uterine bleeding.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

  • When prescribing Menovag, clinicians should consider several safety precautions to minimize risk.
  • Contraindications: known history of thromboembolic disease or estrogen‑dependent neoplasia.
  • Bleeding assessment: monitor for abnormal vaginal bleeding or spotting.
  • Liver function: evaluate hepatic impairment before use.
  • Cardiovascular risk: assess hypertension, smoking status, and age.
  • Pregnancy and lactation: avoid unless clearly indicated by a physician.
  • Store at room temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Estradiol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Combined hormonal contraceptives: additive estrogen effect increasing thrombotic risk.
  • Anticoagulants (warfarin, DOACs): potential for enhanced clotting complications.
  • Selective estrogen receptor modulators (tamoxifen, raloxifene): antagonistic actions reducing therapeutic benefit.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (ketoconazole, itraconazole): may raise estradiol plasma levels.
  • Antihypertensives (ACE inhibitors, beta‑blockers): possible fluid retention exacerbation.
  • Lithium: may affect hormone metabolism and require monitoring.

Frequently Asked Questions

Menovag is a vaginal formulation of estradiol indicated for the treatment of vaginal atrophy and the genitourinary syndrome of menopause. It helps relieve dryness, irritation, itching, and discomfort that occur due to estrogen deficiency in post‑menopausal women or after surgical removal of the ovaries.

Estradiol in Menovag binds to estrogen receptors (ERα and ERβ) in the vaginal epithelium and surrounding tissues. This receptor activation triggers gene transcription that promotes cell proliferation, increased glycogen production, and enhanced blood flow, thereby restoring normal vaginal mucosal thickness and lubrication.

The appropriate dose of Menovag is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual response. Dosage regimens may vary, and the prescriber will provide specific instructions on frequency and duration of use.

Menovag is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefits outweigh the risks. Systemic absorption of estradiol can affect fetal development and milk production, so a healthcare professional should evaluate each case carefully.

To order Menovag, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Compared with oral estradiol or conjugated estrogen preparations, Menovag delivers estrogen directly to the vaginal tissue, resulting in lower systemic exposure and a reduced risk of systemic side effects. This local delivery can provide faster symptom relief for vaginal atrophy while minimizing hepatic first‑pass metabolism.

Menovag should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not refrigerate or freeze unless specifically instructed by the manufacturer.

Menovag is inserted vaginally according to the prescriber’s directions, typically using a clean applicator or the supplied device. The patient should lie down for a few minutes after insertion to allow the tablet to dissolve and the estradiol to be absorbed locally.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and estrogen‑dependent neoplasia such as endometrial hyperplasia or carcinoma. Patients should be monitored for unexplained vaginal bleeding, leg pain, shortness of breath, or other signs of clot formation.

Menovag is contraindicated in individuals with a history of thromboembolic disease, estrogen‑dependent tumors (e.g., breast or endometrial cancer), active or past venous thrombosis, uncontrolled hypertension, or known hypersensitivity to estradiol or any excipients in the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Estradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT